Fujirebio Wins The Scientist's 2025 Top Innovations Award for Groundbreaking Plasma Ratio Blood Test

This prestigious honor celebrates the most innovative medical devices and diagnostic tests that are improving patient outcomes. Fujirebio’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test, the first FDA-cleared in vitro diagnostic blood-based test, uses human plasma that combines the results of Lumipulse G pTau 217 plasma and Lumipulse G /β-Amyloid 1-42-N plasma assays into a ratio of pTau 217 to β-Amyloid 1-42. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio is intended to aid healthcare providers to identify patients with amyloid pathology associated with AD. The test is intended for adult patients aged 50 years and older, presenting at a specialized care setting with signs and symptoms of cognitive decline.

“We are honored to receive this recognition from The Scientist,” said Monte Wiltse, President & CEO of Fujirebio Diagnostics. “This award reflects our team’s commitment to advancing diagnostic science and improving lives through
innovation.”

The Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test uses Fujirebio’s fully automated LUMIPULSE® G1200 system, enabling clinical laboratories across the U.S. to offer a minimally invasive, cost-effective alternative to PET scans and CSF testing. In clinical studies, the test demonstrated a positive predictive value of 92% and a negative predictive value of 97%, offering timely insights to support informed decision-making for clinicians and their patients. 

As part of the award spotlight, The Scientist will feature an editorial article including interviews with Diana Dickson, VP, Clinical & Regulatory Sciences, and neurologist Dr. David Greeley, MD. The article will explore the test’s clinical
significance, its FDA approval journey, and its implications for early diagnosis and treatment planning. 

The editorial will be featured in an upcoming issue of The Scientist Digest and will be supported by promotional
placements, including a full-page advertisement and digital outreach.
 

For more information about the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test, visit Fujirebio’s official product page.

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is an R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms. For more information, please visit www.fujirebio.com.

About The Scientist

The Scientist is the magazine for life science professionals—a publication dedicated to covering a wide range of topics central to the study of cell and molecular biology, genetics, and other life-science fields. Through innovative print articles, online stories, and multimedia features, the magazine explores the latest scientific discoveries, trends in
research, innovative techniques, new technology, business, and careers. It is read by leading researchers in industry and academia who value penetrating analyses and broad perspectives on life-science topics both within and beyond their areas of expertise. Written by prominent scientists and professional journalists, articles in The Scientist are concise, accurate, accessible, and entertaining. For more information, please visit www.the-scientist.com.

Contacts:

• Fujirebio Diagnostics, Inc.
  Janet Detwiler, Executive Assistant to Fujirebo CEO
  detwilerj@fdi.com

• The Scientist
  Charlene Lancaster, Assistant Science Editor
  clancaster@the-scientist.com